BACKGROUND/AIMS: Percutaneous tumor ablation (PTA), such as ethanol injection, is currently accepted as a potentially curative treatment for hepatocellular carcinoma (HCC). Percutaneous tumor ablation is presumed to be relatively non-invasive, but there are few studies on long-term follow-up of liver function after tumor ablation. METHODS: Changes in liver functions were monitored in 227 consecutive patients treated for a solitary HCC nodule by PTA between 1993 and 1997. The liver function evaluated based on Child-Turcotte classification prior to the initial treatment was Child A in 119 (52.4%) patients, B in 81(35.7%), and C in 27 (11.9%). The follow-up period was 46 +/- 21 months. RESULTS: The five-year survival rates of patients in Child A, B, and C group after treatment were respectively 76%, 45%, and 43%. Annual shift rate of Child A to Child B was 7%, and that of Child B to Child C was 14%. Tumor recurrence significantly affected aggravation of liver function in Child A (P = 0.002) but not in Child B patients (P = 0.55). Tumor size at initial treatment influenced changes of liver function in Child B group patients (P = 0.009). CONCLUSIONS: Preservation of liver function may be essential when treating HCC patients with impaired liver function.
BACKGROUND/AIMS: Percutaneous tumor ablation (PTA), such as ethanol injection, is currently accepted as a potentially curative treatment for hepatocellular carcinoma (HCC). Percutaneous tumor ablation is presumed to be relatively non-invasive, but there are few studies on long-term follow-up of liver function after tumor ablation. METHODS: Changes in liver functions were monitored in 227 consecutive patients treated for a solitary HCC nodule by PTA between 1993 and 1997. The liver function evaluated based on Child-Turcotte classification prior to the initial treatment was Child A in 119 (52.4%) patients, B in 81(35.7%), and C in 27 (11.9%). The follow-up period was 46 +/- 21 months. RESULTS: The five-year survival rates of patients in Child A, B, and C group after treatment were respectively 76%, 45%, and 43%. Annual shift rate of Child A to Child B was 7%, and that of Child B to Child C was 14%. Tumor recurrence significantly affected aggravation of liver function in Child A (P = 0.002) but not in Child B patients (P = 0.55). Tumor size at initial treatment influenced changes of liver function in Child B group patients (P = 0.009). CONCLUSIONS: Preservation of liver function may be essential when treating HCC patients with impaired liver function.
Authors: Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; K Hamamura; Y Imai; H Yoshida; S Shiina; M Omata Journal: Hepatology Date: 2000-12 Impact factor: 17.425
Authors: T Seki; M Wakabayashi; T Nakagawa; T Itho; T Shiro; K Kunieda; M Sato; S Uchiyama; K Inoue Journal: Cancer Date: 1994-08-01 Impact factor: 6.860
Authors: E Christensen; P Schlichting; L Fauerholdt; C Gluud; P K Andersen; E Juhl; H Poulsen; N Tygstrup Journal: Hepatology Date: 1984 May-Jun Impact factor: 17.425
Authors: M Ebara; M Ohto; N Sugiura; K Kita; M Yoshikawa; K Okuda; F Kondo; Y Kondo Journal: J Gastroenterol Hepatol Date: 1990 Nov-Dec Impact factor: 4.029
Authors: Hyun Seok Lee; Soo Young Park; Sung Kook Kim; Young Oh Kweon; Won Young Tak; Chang Min Cho; Seong Woo Jeon; Min Kyu Jung; Hyun Gu Park; Dong Wook Lee; So Young Choi Journal: Clin Mol Hepatol Date: 2012-09-25